Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nacer Abrouk

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Life Sciences in Space Research|November 6, 2022
RRx-001 and the "Right stuff": Protection and treatment in outer spaceBryan Oronsky, Scott Caroen, Nacer Abrouk, et al.
American Journal of Cancer Research|May 9, 2022
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenograftsTony Reid, Bryan Oronsky, Nacer Abrouk, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2018
A note on improved statistical approaches to account for pseudoprogressionNacer Abrouk, Bryan Oronsky, Scott Caroen, et al.
Frontiers in Immunology|March 24, 2023
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)Tony Reid, Bryan Oronsky, Scott Caroen, et al.
Journal of Cancer|August 1, 2022
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)Bryan Oronsky, Nacer Abrouk, Scott Caroen, et al.
Cancer Metastasis Reviews|August 23, 2024
Lost at SCLC: a review of potential platinum sensitizersBryan Oronsky, Nacer Abrouk, Li Mao, et al.
Clinical Colorectal Cancer|December 18, 2022
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal CancerTony R Reid, Nacer Abrouk, Scott Caroen, et al.
Clinical and Translational Science|June 29, 2023
Data Management 101 for drug developers: A peek behind the curtainBryan Oronsky, Erica Burbano, Meaghan Stirn, et al.
ANZ Journal of Surgery|April 19, 2012
Safety and efficacy of extended-release bupivacaine local anaesthetic in open hernia repair: a randomized controlled trialAfif Hadj, Andrew Hadj, Anthony Hadj, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Life Sciences in Space Research|November 6, 2022
RRx-001 and the "Right stuff": Protection and treatment in outer spaceBryan Oronsky, Scott Caroen, Nacer Abrouk, et al.
American Journal of Cancer Research|May 9, 2022
The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenograftsTony Reid, Bryan Oronsky, Nacer Abrouk, et al.
Frontiers in Oncology|June 21, 2023
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastomaHoward Fine, Tony Reid, Scott Caroen, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2018
A note on improved statistical approaches to account for pseudoprogressionNacer Abrouk, Bryan Oronsky, Scott Caroen, et al.
Frontiers in Immunology|March 24, 2023
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)Tony Reid, Bryan Oronsky, Scott Caroen, et al.
Journal of Cancer|August 1, 2022
A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)Bryan Oronsky, Nacer Abrouk, Scott Caroen, et al.
Cancer Metastasis Reviews|August 23, 2024
Lost at SCLC: a review of potential platinum sensitizersBryan Oronsky, Nacer Abrouk, Li Mao, et al.
Clinical Colorectal Cancer|December 18, 2022
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal CancerTony R Reid, Nacer Abrouk, Scott Caroen, et al.
Clinical and Translational Science|June 29, 2023
Data Management 101 for drug developers: A peek behind the curtainBryan Oronsky, Erica Burbano, Meaghan Stirn, et al.
ANZ Journal of Surgery|April 19, 2012
Safety and efficacy of extended-release bupivacaine local anaesthetic in open hernia repair: a randomized controlled trialAfif Hadj, Andrew Hadj, Anthony Hadj, et al.
Pageof 2